Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

NCT00279422 is registered in ClinicalTrials.gov with Facet Biotech as lead sponsor.

NCT NCT00279422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00279422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Lead sponsor
Facet Biotech
Phase
Phase 2/3
Overall status
Terminated
Start date
February 28, 2006
Completion date
August 31, 2007
Enrollment
127 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis